Literature DB >> 28078560

Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer.

Tengyue Zeng1, Libing Zhu2, Min Liao1, Wenli Zhuo1, Shunliang Yang1, Weizhen Wu1, Dong Wang3.   

Abstract

Pyrroline-5-carboxylate reductase 1 (PYCR1) is an enzyme involved in cell metabolism, which has been shown to be up-regulated in cancers. However, the functions of PYCR1 in prostate cancers (PCa) are still largely unknown. In the present study, we found that PYCR1 was highly expressed in prostate cancer tissues and then knocked down PYCR1 in PCa cell lines (DU145, PC-3 and LNCap) via lentivirus-mediated gene delivery and analyzed its biological function. Both qRT-PCR and western blotting indicated that PYCR1 was suppressed efficiently after sh-PYCR1 infection. Further analysis indicated knockdown of PYCR1 significantly inhibited PCa cell growth and colony formation ability. The inhibition effects on growth were likely due to G2/M-phase arrest and enhanced cell apoptosis, as determined by flow cytometer analysis. At last, we verified the expression levels of cell cycle regulatory proteins, including CDK1, CDK2, CDK4 and Cyclin B1 were all downregulated and cell apoptotic-related proteins, including cleaved caspase 3 and cleaved PARP were increased in PCa cells after PYCR1 knockdown. Furthermore, PYCR1 has been shown not to be directly regulated by androgen receptor (AR) levels. These results show the functions of PYCR1 in PCa tumorigenesis for the first time and suggest that PYCR1 might be a good potential therapy approach for treating PCa.

Entities:  

Keywords:  AR signaling; Apoptosis; Cell cycle; Cell proliferation; PYCR1; Prostate cancer

Mesh:

Substances:

Year:  2017        PMID: 28078560     DOI: 10.1007/s12032-016-0870-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

1.  Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines.

Authors:  S A Maxwell; G E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells.

Authors:  P Geck; J Szelei; J Jimenez; T M Lin; C Sonnenschein; A M Soto
Journal:  J Steroid Biochem Mol Biol       Date:  1997 Nov-Dec       Impact factor: 4.292

3.  A novel mutation in PYCR1 causes an autosomal recessive cutis laxa with premature aging features in a family.

Authors:  Dar-Shong Lin; Chun-Yan Yeung; Hsuan-Liang Liu; Che-Sheng Ho; Chyong-Hsin Shu; Chih-Kuang Chuang; Yu-Wen Huang; Tsu-Yen Wu; Zon-Darr Huang; Yuan-Ren Jian; Shuan-Pei Lin
Journal:  Am J Med Genet A       Date:  2011-05-12       Impact factor: 2.802

4.  Defect in proline synthesis: pyrroline-5-carboxylate reductase 1 deficiency leads to a complex clinical phenotype with collagen and elastin abnormalities.

Authors:  Rita Kretz; Bita Bozorgmehr; Mohamad Hasan Kariminejad; Marianne Rohrbach; Ingrid Hausser; Alessandra Baumer; Matthias Baumgartner; Cecilia Giunta; Ariana Kariminejad; Johannes Häberle
Journal:  J Inherit Metab Dis       Date:  2011-04-13       Impact factor: 4.982

5.  DJ-1 cooperates with PYCR1 in cell protection against oxidative stress.

Authors:  Tatsuki Yasuda; Yusuke Kaji; Tomohiro Agatsuma; Takeshi Niki; Mitsuhiro Arisawa; Satoshi Shuto; Hiroyoshi Ariga; Sanae M M Iguchi-Ariga
Journal:  Biochem Biophys Res Commun       Date:  2013-06-04       Impact factor: 3.575

6.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

7.  Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress.

Authors:  Navasona Krishnan; Martin B Dickman; Donald F Becker
Journal:  Free Radic Biol Med       Date:  2007-11-12       Impact factor: 7.376

Review 8.  Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.

Authors:  H Bonkhoff; K Remberger
Journal:  Prostate       Date:  1996-02       Impact factor: 4.104

9.  Genotype-phenotype spectrum of PYCR1-related autosomal recessive cutis laxa.

Authors:  Aikaterini Dimopoulou; Björn Fischer; Thatjana Gardeitchik; Phillipe Schröter; Hülya Kayserili; Claire Schlack; Yun Li; Jaime Moritz Brum; Ingeborg Barisic; Marco Castori; Christiane Spaich; Elaine Fletcher; Zeina Mahayri; Meenakshi Bhat; Katta M Girisha; Katherine Lachlan; Diana Johnson; Shubha Phadke; Neerja Gupta; Martina Simandlova; Madhulika Kabra; Albert David; Leo Nijtmans; David Chitayat; Beyhan Tuysuz; Francesco Brancati; Stefan Mundlos; Lionel Van Maldergem; Eva Morava; Bernd Wollnik; Uwe Kornak
Journal:  Mol Genet Metab       Date:  2013-08-24       Impact factor: 4.797

Review 10.  Epidemiology of prostate cancer in the Asia-Pacific region.

Authors:  Peter D Baade; Danny R Youlden; Susanna M Cramb; Jeff Dunn; Robert A Gardiner
Journal:  Prostate Int       Date:  2013-06-30
View more
  40 in total

1.  Identification of lncRNA TRPM2-AS/miR-140-3p/PYCR1 axis's proliferates and anti-apoptotic effect on breast cancer using co-expression network analysis.

Authors:  Tong Sun; Yan Song; Hong Yu; Xiao Luo
Journal:  Cancer Biol Ther       Date:  2019-02-27       Impact factor: 4.742

2.  Resolving the cofactor-binding site in the proline biosynthetic enzyme human pyrroline-5-carboxylate reductase 1.

Authors:  Emily M Christensen; Sagar M Patel; David A Korasick; Ashley C Campbell; Kurt L Krause; Donald F Becker; John J Tanner
Journal:  J Biol Chem       Date:  2017-03-03       Impact factor: 5.157

Review 3.  Proline metabolism in cancer.

Authors:  Pengyu Geng; Wangshu Qin; Guowang Xu
Journal:  Amino Acids       Date:  2021-08-14       Impact factor: 3.520

4.  PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma.

Authors:  Xiyi Wei; Xi Zhang; Shuai Wang; Yichun Wang; Chengjian Ji; Liangyu Yao; Ninghong Song
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

Review 5.  Structure, biochemistry, and gene expression patterns of the proline biosynthetic enzyme pyrroline-5-carboxylate reductase (PYCR), an emerging cancer therapy target.

Authors:  Alexandra N Bogner; Kyle M Stiers; John J Tanner
Journal:  Amino Acids       Date:  2021-05-18       Impact factor: 3.520

Review 6.  Reprogramming of mitochondrial proline metabolism promotes liver tumorigenesis.

Authors:  Zhaobing Ding; Russell E Ericksen; Qian Yi Lee; Weiping Han
Journal:  Amino Acids       Date:  2021-02-28       Impact factor: 3.520

7.  Phenyl-substituted aminomethylene-bisphosphonates inhibit human P5C reductase and show antiproliferative activity against proline-hyperproducing tumour cells.

Authors:  Giuseppe Forlani; Giuseppe Sabbioni; Daniele Ragno; Davide Petrollino; Monica Borgatti
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 8.  Isozymes of P5C reductase (PYCR) in human diseases: focus on cancer.

Authors:  Chien-An A Hu
Journal:  Amino Acids       Date:  2021-07-22       Impact factor: 3.520

Review 9.  PYCR, a key enzyme in proline metabolism, functions in tumorigenesis.

Authors:  Yutong Li; Juntao Bie; Chen Song; Minghui Liu; Jianyuan Luo
Journal:  Amino Acids       Date:  2021-07-17       Impact factor: 3.520

10.  Deciphering the effects of PYCR1 on cell function and its associated mechanism in hepatocellular carcinoma.

Authors:  Yanzhen Xu; Wenpu Zuo; Xiao Wang; Qinle Zhang; Xiang Gan; Ning Tan; Wenxian Jia; Jiayi Liu; Zhouquan Li; Bo Zhou; Dong Zhao; Zhibin Xie; Yanjun Tan; Shengfeng Zheng; Chengwu Liu; Hongtao Li; Zhijian Chen; Xiaoli Yang; Zhaoquan Huang
Journal:  Int J Biol Sci       Date:  2021-06-01       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.